BioWorld

June 24, 2004

View Archived Issues

Safety Issues Force IntraBiotics To Halt Iseganan VAP Program

Just as researchers geared up to start a second pivotal trial of iseganan in ventilator-associated pneumonia (VAP), the floor fell from beneath IntraBiotics Pharmaceuticals Inc. Wednesday. (BioWorld Today) Read More

Exelixis Begins Phase III Trial Of XL119 In Bile Duct Cancer

Read More

PTC Raises Another $15M To Close Series E At $50M

Read More

Millennium Shifts Integrilin In Europe From Schering To GSK

Read More

Kosan, Roche Stop Colorectal Cancer Trial, Shift To Prostate

Read More

Other News To Note

Read More